Before undergoing radioactive iodine therapy for Graves disease, what necessary test should a patient take?

Before undergoing radioactive iodine therapy for Graves disease, it is essential to test for beta-human chorionic gonadotropin (hCG). This test is particularly important in women of childbearing age, as pregnancy can significantly affect the safety and effectiveness of radioactive iodine treatment.

If a woman is pregnant, radioactive iodine can potentially harm the developing fetus, leading to serious consequences. Therefore, ensuring that a patient is not pregnant is a critical step before proceeding with the therapy. The detection of hCG helps confirm pregnancy status and ensures appropriate decision-making regarding the timing and safety of treatment.

While thyroid function tests are vital for assessing the patient's condition and managing Graves disease, the necessity of checking for hCG focuses on the risks associated with radioactive iodine in a pregnant woman.